{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:24:02Z","timestamp":1787739842450,"version":"build-2784847793"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"\n Purpose<\/jats:title>\n To determine which subgroup of children would best benefit from 0.01% atropine eyedrop.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n This\n post hoc<\/jats:italic>\n secondary analysis assessed 68 subjects. Placebo for the first year and 0.01% atropine eye drops for the second year. According to the annual spherical equivalent progression (SEP) during the first year, subjects were subdivided into three groups: slow, moderate and fast (annual SEP &gt; \u22120.50 D, \u22121.00 D &lt; annual SEP \u2264 \u22120.50 D, annual SEP \u2264 \u22121.00 D, respectively).\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n After 1\u00a0year of 0.01% atropine treatment, SEP was \u22120.37 \u00b1 0.23 D, \u22120.57 \u00b1 0.38 D, and \u22120.68 \u00b1 0.49 D in the slow, moderate, and fast progression groups (P = 0.17). The group with faster SEP during the first year still showed faster SEP after treatment. The reduction of SEP (SEP of the second year minus SEP of the first year) in the moderate group was more than that in the slow group (0.22 \u00b1 0.37 D vs. \u22120.10 \u00b1 0.21 D, P = 0.007); the fast group was more than that in the slow group (0.57 \u00b1 0.55 D vs. \u22120.10 \u00b1 0.21 D, P &lt; 0.001) and the moderate group (0.57 \u00b1 0.55 D vs. 0.22 \u00b1 0.37 D, P = 0.02). Faster SEP before treatment is related to the reduction efficiency (\u03b2 = \u22120.5, P = 0.01).<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Faster SEP before treatment is associated with a better treatment response to 0.01% atropine eye drops, with greater reduction in SEP after treatment. However, no significant association was found between baseline progression and axial elongation changes. Children with slow SEP cannot get significant myopia control benefit from 1-year 0.01% atropine treatment.<\/jats:p>\n <\/jats:sec>\n \n Clinical Trial Registration<\/jats:title>\n \n clinicaltrials.gov<\/jats:ext-link>\n , identifier ChiCTR-IOR-17013898.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fphar.2026.1871905","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T09:56:46Z","timestamp":1787738206000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Pretreatment myopia progression is associated with the response to 0.01% atropine: a post-hoc secondary analysis of a randomized controlled trial"],"prefix":"10.3389","volume":"17","author":[{"given":"Shi-Fei","family":"Wei","sequence":"first","affiliation":[{"name":"Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Key Laboratory of Ophthalmology and Visual Science, Beijing Tongren Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ling","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Beijing Shijitan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Yun","family":"Sun","sequence":"additional","affiliation":[{"name":"Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Key Laboratory of Ophthalmology and Visual Science, Beijing Tongren Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Zai","family":"An","sequence":"additional","affiliation":[{"name":"Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Key Laboratory of Ophthalmology and Visual Science, Beijing Tongren Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Tong","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Peking University First Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-He","family":"Gan","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Shanghai East Hospital, School of Medicine, Tongji University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Ning","family":"Cai","sequence":"additional","affiliation":[{"name":"Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Key Laboratory of Ophthalmology and Visual Science, Beijing Tongren Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian-Qian","family":"Song","sequence":"additional","affiliation":[{"name":"Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Key Laboratory of Ophthalmology and Visual Science, Beijing Tongren Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Ming","family":"Li","sequence":"additional","affiliation":[{"name":"Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Key Laboratory of Ophthalmology and Visual Science, Beijing Tongren Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning-Li","family":"Wang","sequence":"additional","affiliation":[{"name":"Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Key Laboratory of Ophthalmology and Visual Science, Beijing Tongren Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1007\/s00417-022-05863-8","article-title":"Effect of low-dose atropine eyedrops on pupil metrics: results after half a year of treatment and cessation","volume":"261","author":"Bai","year":"2023","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41572-020-00231-4","article-title":"Myopia","volume":"6","author":"Baird","year":"2020","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1111\/opo.13379","article-title":"Can we really distinguish \u2018responders\u2019 from \u2018non-responders\u2019 to myopia control interventions?","volume":"44","author":"Brennan","year":"2024","journal-title":"Ophthalmic Physiol. Opt."},{"key":"B4","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1111\/opo.12990","article-title":"Factors determining the myopia control effect of an orthokeratology lens: a two-year multi-level model","volume":"42","author":"Chen","year":"2022","journal-title":"Ophthalmic Physiol. Opt."},{"key":"B5","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ophtha.2015.07.004","article-title":"Five-year clinical trial on atropine for the treatment of myopia 2: myopia control with atropine 0.01% eyedrops","volume":"123","author":"Chia","year":"2016","journal-title":"Ophthalmology"},{"key":"B6","first-page":"577","article-title":"Setting the individual file of ocular refractive development of children is the primary procedure in the prevention of myopia","volume":"45","author":"Chu","year":"2009","journal-title":"Chin. J. Ophthalmol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1016\/j.ophtha.2006.05.062","article-title":"Atropine for the treatment of childhood myopia","volume":"113","author":"Chua","year":"2006","journal-title":"Ophthalmology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1136\/bjophthalmol-2021-320318","article-title":"Establishing a method to estimate the effect of antimyopia management options on lifetime cost of myopia","volume":"107","author":"Fricke","year":"2022","journal-title":"Br. J. Ophthalmol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"101530","DOI":"10.1016\/j.clae.2021.101530","article-title":"Efficacy, predictability and safety of long-term orthokeratology: an 18-year follow-up study","volume":"45","author":"Gispets","year":"2022","journal-title":"Cont. Lens Anterior Eye"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.ophtha.2016.01.006","article-title":"Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050","volume":"123","author":"Holden","year":"2016","journal-title":"Ophthalmology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1177\/11206721211038817","article-title":"Analysis of treatment response about low-dose (0.01%) atropine eye-drops in myopic children","volume":"32","author":"Jeon","year":"2021","journal-title":"Eur. J. Ophthalmol."},{"key":"B23","volume-title":"The Impact of Myopia and High Myopia. Report of the Joint World Health Organization-Brien Holden Vision Institute Global Scientific Meeting on Myopia","author":"Mariotti","year":"2015"},{"key":"B12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1167\/iovs.62.5.6","article-title":"IMI prevention of myopia and its progression","volume":"62","author":"Jonas","year":"2021","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"B13","doi-asserted-by":"publisher","first-page":"7380","DOI":"10.1038\/s41598-022-10978-3","article-title":"Characteristics of responders to atropine 0.01% as treatment in Asian myopic children","volume":"12","author":"Lee","year":"2022","journal-title":"Sci. Rep."},{"key":"B14","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1136\/bjophthalmol-2019-314752","article-title":"Practice patterns to decrease myopia progression differ among paediatric ophthalmologists around the world","volume":"104","author":"Leshno","year":"2020","journal-title":"Br. J. Ophthalmol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"348","DOI":"10.3109\/09286586.2013.842596","article-title":"Design, methodology and baseline data of a school-based cohort study in central China: the Anyang childhood eye study","volume":"20","author":"Li","year":"2013","journal-title":"Ophthalmic Epidemiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"4734","DOI":"10.1167\/iovs.14-15474","article-title":"Time outdoors and myopia progression over 2 years in Chinese children: the Anyang childhood eye study","volume":"56","author":"Li","year":"2015","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1001\/jamaophthalmol.2021.3695","article-title":"Effect of school-based family health education via social media on children's myopia and parents' awareness: a randomized clinical trial","volume":"139","author":"Li","year":"2021","journal-title":"JAMA Ophthalmol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/j.ophtha.2020.12.036","article-title":"Age effect on treatment responses to 0.05%, 0.025%, and 0.01% atropine: low-concentration atropine for myopia progression study","volume":"128","author":"Li","year":"2021","journal-title":"Ophthalmology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1001\/jamapediatrics.2022.3542","article-title":"Effect of text messaging parents of school-aged children on outdoor time to control myopia: a randomized clinical trial","volume":"176","author":"Li","year":"2022","journal-title":"JAMA Pediatr."},{"key":"B20","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.ajo.2015.01.029","article-title":"Risk factors for progressive myopia in the atropine therapy for myopia study","volume":"159","author":"Loh","year":"2015","journal-title":"Am. J. Ophthalmol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1167\/tvst.9.13.12","article-title":"Annual myopia progression and subsequent 2-year myopia progression in Singaporean children","volume":"9","author":"Matsumura","year":"2020","journal-title":"Transl. Vis. Sci. Tech."},{"key":"B22","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1097\/OPX.0000000000001883","article-title":"The limited value of prior change in predicting future progression of juvenile-onset myopia","volume":"99","author":"Mutti","year":"2022","journal-title":"Optom. Vis. Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"21748","DOI":"10.1038\/s41598-021-00923-1","article-title":"A multicenter Spanish study of atropine 0.01% in childhood myopia progression","volume":"11","author":"P\u00e9rez-Flores","year":"2021","journal-title":"Sci. Rep."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1016\/j.ophtha.2017.05.032","article-title":"Atropine for the prevention of myopia progression in children: a report by the American academy of ophthalmology","volume":"124","author":"Pineles","year":"2017","journal-title":"Ophthalmology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1001\/jamaophthalmol.2023.2855","article-title":"Low-dose 0.01% atropine eye drops vs placebo for myopia control: a randomized clinical trial","volume":"141","author":"Repka","year":"2023","journal-title":"JAMA Ophthalmol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1007\/s00431-023-04921-5","article-title":"Prevention of myopia shift and myopia onset using 0.01% atropine in premyopic children - a prospective, randomized, double-masked, and crossover trial","volume":"182","author":"Wang","year":"2023","journal-title":"Eur. J. Pediatr."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1136\/bjo-2023-323468","article-title":"Normative value of hyperopia reserve and myopic shift in Chinese children and adolescents aged 3-16 years","volume":"108","author":"Wang","year":"2024","journal-title":"Br. J. Ophthalmol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1167\/iovs.18-24363","article-title":"Refractive errors in university students in central China: the anyang university students eye study","volume":"59","author":"Wei","year":"2018","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1001\/jamaophthalmol.2020.3820","article-title":"Safety and efficacy of low-dose atropine eyedrops for the treatment of myopia progression in Chinese children: a randomized clinical trial","volume":"138","author":"Wei","year":"2020","journal-title":"JAMA Ophthalmol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1111\/aos.15235","article-title":"Myopia progression after cessation of low-dose atropine eyedrops treatment: a two-year randomized, double-masked, placebo-controlled, cross-over trial","volume":"101","author":"Wei","year":"2022","journal-title":"Acta Ophthalmol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1089\/jop.2011.0027","article-title":"The long-term results of using low-concentration atropine eye drops for controlling myopia progression in schoolchildren","volume":"27","author":"Wu","year":"2011","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"B33","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","article-title":"Low-concentration atropine for myopia progression (LAMP) study: a randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control","volume":"126","author":"Yam","year":"2019","journal-title":"Ophthalmology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"01081","DOI":"10.3389\/fphar.2020.01081","article-title":"Analysis of factors that may affect the effect of atropine 0.01% on myopia control","volume":"11","author":"Zhang","year":"2020","journal-title":"Front. Pharmacology"},{"key":"B35","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1136\/bjo-2023-323887","article-title":"Advances in myopia control strategies for children","volume":"109","author":"Zhang","year":"2025","journal-title":"Br. J. Ophthalmol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1871905\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T09:56:47Z","timestamp":1787738207000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1871905\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":35,"alternative-id":["10.3389\/fphar.2026.1871905"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1871905","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"article-number":"1871905"}}